New pain drug tested with HIV pill in healthy volunteers

NCT ID NCT07570069

First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 4 times

Summary

This early-stage study is testing how a new pain medication called suzetrigine interacts with efavirenz, a drug used to treat HIV. The trial involves 18 healthy adults and measures how the body processes suzetrigine when taken alone versus with efavirenz. The goal is to check for any safety issues or changes in drug levels, not to treat pain directly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Suzetrigine (also called SUZ, Journavx) and efavirenz

What this could lead to

If successful, this study could help doctors understand how to safely combine suzetrigine with other drugs that affect the same liver enzymes.

What could go wrong

This is a very early, small study in healthy volunteers, not patients. It only looks at drug levels and safety, not whether suzetrigine works for pain. Results may not apply to people with medical conditions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ICON - Utah - Salt Lake City Office

    Salt Lake City, Utah, 84124, United States